22157.jpg
Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies Bundle Report 2022: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis
August 09, 2022 06:18 ET | Research and Markets
Dublin, Aug. 09, 2022 (GLOBE NEWSWIRE) -- The "Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and...
22157.jpg
Global CAR-T Therapy Market Report 2022-2026 & 2031: Focus on Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA
August 03, 2022 06:03 ET | Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Therapy Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering. The global CAR-T therapy market is expected to...
Global Checkpoint Inhibitors Markets, Analysis & Forecasts, 2016-2021, 2021-2026F, 2031F Featuring AstraZeneca, Bristol-Myers Squibb, Merck & Co, Roche, Pfizer, Incyte, Novartis, and NewLink Genetics
July 29, 2022 06:23 ET | Research and Markets
Dublin, July 29, 2022 (GLOBE NEWSWIRE) -- The "Checkpoint Inhibitors Global Market Report 2022: By Drug, By Application, By End-Users" report has been added to ResearchAndMarkets.com's offering. ...
22157.jpg
Claudin 6: An Exceptionally Attractive Target for Drug Discovery and Development
July 25, 2022 06:53 ET | Research and Markets
Dublin, July 25, 2022 (GLOBE NEWSWIRE) -- The "Claudin 6: A Target Opportunity To Develop Effector-Enhanced Drug Modalities" report has been added to ResearchAndMarkets.com's offering. Claudin 6...
Insights on the Natural Killer Cells Therapeutics Global Market to 2027 - by Therapeutics, Application, End-user and Region
July 01, 2022 07:13 ET | Research and Markets
Dublin, July 01, 2022 (GLOBE NEWSWIRE) -- The "Natural Killer Cells Therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to...
22157.jpg
Outlook on the CAR-T Cell Therapies Industry - In-depth Review of the Various Patents and Affiliated IP Documents
April 25, 2022 05:58 ET | Research and Markets
Dublin, April 25, 2022 (GLOBE NEWSWIRE) -- The "CAR-T Cell Therapies: Intellectual Property Landscape (Featuring Historical and Contemporary Patent Filing Trends, Prior Art Search Expressions,...
Global Car T Cell Therapy Market (2021 to 2028) - Size, Share, Outlook, and Opportunity Analysis
February 14, 2022 05:43 ET | Research and Markets
Dublin, Feb. 14, 2022 (GLOBE NEWSWIRE) -- The "Car T Cell Therapy Market" report has been added to ResearchAndMarkets.com's offering. Chimeric antigen receptor (CAR) T-cell therapy is a type of...
Roots-Analysis-Logo.png
The CAR-T therapies market is characterized by a healthy pipeline of promising therapies, and is projected to be worth around USD 14 Billion in 2030, claims Roots Analysis
April 06, 2021 08:45 ET | Roots Analysis
London, April 06, 2021 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “CAR-T Therapies Market (3rd Edition) by Target Indications (NHL, Multiple Myeloma, Chronic Lymphocytic...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces Poseida’s Exercise of Four Commercial License Options for UniDabs to Targets for Advanced CAR T-cell Therapies
November 23, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical stage next generation, multi-specific antibody therapeutics company, announced today that in 2020, Poseida exercised four...
Teneo_logo_FINAL_whitebkgnd.png
Teneobio Announces a Research Collaboration and License Agreement With ArsenalBio
October 21, 2020 08:00 ET | TeneoBio, Inc
NEWARK, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies to treat cancer, today announced that it has...